Commentary Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/cardiology.2.014
Blood Pressure Lowering May Decrease Cognitive Decline; But Are We Ready to Lower Blood Pressure in the Real World?
Madhuri Ramakrishnan1, Gary Gronseth2, Aditi Gupta1,2,3*
- 1Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City,Kansas, United States
- 2Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, United States
- 3Alzheimer’s Disease Center, University of Kansas Medical Center, Kansas City, Kansas, United States
Corresponding Author
Aditi Gupta, agupta@kumc.edu
Received Date: March 24, 2021
Accepted Date: July 19, 2021
Ramakrishnan M, Gronseth G, Gupta A. Blood Pressure Lowering May Decrease Cognitive Decline; But Are We Ready to Lower Blood Pressure in the Real World?. J Clin Cardiol. 2021; 2(2):34-38.
Copyright: © 2021 Ramakrishnan M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Blood Pressure Lowering May Decrease Cognitive Decline; But Are We Ready to Lower Blood Pressure in the Real World?
Dementia and hypertension are highly prevalent, epidemiologically related chronic conditions disproportionately affecting older persons; approximately 97% of persons with dementia and 66% with hypertension are over the age of 65.
Evaluation and Management of chronic Hypertension in Pregnancy
Chronic hypertension is present in 1-2% of pregnant women. Women with chronic hypertension are at an increased risk of maternal and perinatal complications when compared with normotensive women.
Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Pulmonary Arterial Hypertension (PAH) represents a rare but devastating disease due to small pulmonary arterial vessels remodelling and increased pulmonary vascular resistance leading to right ventricular dysfunction, right heart failure and death.
Aldosterone Synthase Inhibitors for Treatment of Hypertension and Chronic Kidney Disease
Aldosterone excess is known to worsen hypertension and kidney function. Three selective aldosterone synthase inhibitors (ASIs) were evaluated in 3 phase 2 trials. In the first study, the ASI baxdrostat 2 mg orally once daily decreased systolic blood pressure (SBP) by 11.0 mmHg compared with placebo after 12 weeks in patients with treatment-resistant hypertension. In the second study including patients with uncontrolled hypertension, placebo-corrected reduction in SBP with lorundrostat 50 mg once daily was 9.6 mmHg after 8 weeks.